863288-34-0
CJC-1295 (no DAC)
Tetra-substituted GHRH(1-29) analogue without the drug affinity complex. Short-acting.
Typical release99.0%
From
£42.00
In stock
Growth Factor & Secretagogue
Sermorelin
GRF(1-29) · GHRH(1-29) amide
The native GHRH(1-29) fragment, unmodified. The reference sequence for GHRH analogue work.
Total, ex VAT
£52.00
- Released at ≥ 98.0% (RP-HPLC, area %)
- Identity confirmed by ESI-MS against theoretical mass
- Batch certificate matched to the vial, verifiable online
- Same working day dispatch before 14:00, tracked
For laboratory research use only. Not for human or veterinary use, and not a medicine, food or cosmetic. Sold to qualified researchers and institutions who accept responsibility for safe handling and lawful use.
Compound data
What is in the vial
Indicative values for this line. The certificate issued with your batch is the authoritative record and reports the measured figures for the material you receive.
- CAS number
- 86168-78-7
- Molecular formula
- C149H246N44O42S
- Average mass
- 3357.88 g/mol
- Residues
- 29
- Class
- Native GHRH(1-29) fragment
- Form as supplied
- Lyophilised powder
- Appearance
- White to off-white lyophilised powder
- Purity specification
- ≥ 98.0% (RP-HPLC, area %)
- Solubility
- Soluble in sterile or bacteriostatic water.
- Storage
- Lyophilised: −20 °C, desiccated and dark. Reconstituted: 2–8 °C.
Targets and pathways
- Growth hormone-releasing hormone receptor (GHRHR)
Overview
About Sermorelin
Sermorelin is the first 29 residues of human GHRH — the shortest fragment retaining full receptor activity — with a C-terminal amide. It is the unmodified reference against which every stabilised GHRH analogue is compared, which is its principal value in research.
Because it carries no substitutions, it is cleaved rapidly by DPP-4 at the position 2 alanine. That short duration is a limitation in most applications and precisely the point in others: comparing sermorelin against D-Ala2-substituted analogues is how the contribution of DPP-4 resistance is quantified.
In short
- Native GHRH(1-29), the shortest fully active fragment
- No stabilising substitutions — rapidly cleaved by DPP-4
- The unmodified comparator for stabilised GHRH analogues
- Released at ≥ 98.0% area-percent by RP-HPLC
Where it is used
Research applications
Analogue benchmarking
Provides the unmodified baseline against which the duration gain from D-Ala2 and other substitutions is measured.
GHRHR pharmacology
Used to characterise the receptor with its native ligand fragment rather than a modified analogue.
DPP-4 substrate studies
Its rapid cleavage makes it a convenient substrate in work on DPP-4 activity itself.
Handling
Reconstitution and stability
Reconstitution
Reconstitute with sterile or bacteriostatic water added slowly against the inner wall of the vial. Allow the cake to dissolve without agitation, swirling gently if required. Do not vortex or shake.
Stability
Lyophilised at −20 °C, desiccated and protected from light, stable for at least 24 months. Reconstituted and held at 2–8 °C, use within 28 days. Avoid repeated freeze-thaw.
Notes
- Bring the vial to room temperature before opening so atmospheric moisture does not condense onto cold powder.
- Record the reconstitution date on the vial; concentration drift between runs is usually evaporation, not synthesis variance.
- Aliquot at first reconstitution where the working programme needs more than a few withdrawals.
Laboratory reference
Reconstitution calculator
Enter the fill weight on the vial and the diluent volume you intend to add. The calculator returns the resulting solution concentration and the volume that contains a given mass.
- Concentration
- 2.500 mg/mL · 2500 µg/mL
- Volume containing target mass
- 100.0 µL · 0.1000 mL
Figures are mass-to-volume arithmetic for laboratory preparation of Sermorelin and take no account of net peptide content, which is stated on the batch certificate and should be applied to the fill weight before calculating. Nothing here constitutes dosing, administration or clinical guidance of any kind.
Published work
What the literature reports
Summaries of published findings, provided as research reference. These describe work done by others in preclinical and clinical settings; they are not claims about this material or outcomes for any reader.
Fragment activity
Establishment that GHRH(1-29) retains full biological activity of the 44-residue parent hormone.
Rivier et al., Nature, 1982
GHRH receptor signalling
Comprehensive review of receptor pharmacology and the somatotropic axis.
Frohman & Jansson, Endocrine Reviews
Questions
Sermorelin — asked and answered
Something not covered here? Ask us directly — technical questions reach someone who runs the assays.
- Why use an unmodified analogue at all?
- As a comparator. Every claim about what a substitution adds needs an unsubstituted reference, and sermorelin is it.
- Is it stable in solution?
- The lyophilised powder is stable; the peptide's short in-preparation duration is enzymatic, not a storage problem. Solution shelf life is 28 days at 2–8 °C.
- Does it contain methionine?
- Yes, one residue. Expect mild oxidation sensitivity in ageing solutions.
Same class
Others in Growth Factor & Secretagogue
170851-70-4
Most orderedIpamorelin
Selective ghrelin receptor agonist pentapeptide with minimal cross-activity.
Typical release99.2%From
£34.00
In stock
218949-48-5
Tesamorelin
Full-length GHRH(1-44) with an N-terminal hexenoyl group for protease resistance.
Typical release98.6%From
£114.00
In stock
87616-84-0
GHRP-6
First-generation hexapeptide secretagogue at GHS-R1a, with characteristic off-target endocrine activity.
Typical release99.0%From
£29.00
In stock
Important
Sermorelin is supplied strictly for laboratory research and analytical use. It is not a medicine, food, cosmetic or veterinary product; it is not for human or animal consumption; and it is not intended to diagnose, treat, cure or prevent any condition. It is not manufactured, tested or released to any standard that would support administration to humans or animals. Information on this page is compiled for research reference and is not medical advice. No dosing, administration or therapeutic guidance is given or implied. By ordering you confirm you are a qualified researcher or institution and accept responsibility for safe handling and lawful use.